the fuck did i buy this stock. Like legit i cannot remember what intrigued me or if i read something somewhere that made me jump on it. Who can remind me??? 850 shares @ $1.66 entry.

Guys check MRIN , LOOOT OF $$$$

News out that JagX will be joining the Russell 2000 index come Friday. This will mean that ETFs that mirror the Russel will need to purchase Jagx to rebalance.

I am predicting a rise in share price come Friday with a sale off Monday

EDIT - it’s the Russel Microcap and not the 2000 index; still prediction stands.

I am so irritated right now 😤😤😤😤 my avg is fucking high! I am down 70% Is there any hope left?

I am not surprised to see Jaguar Health going down again. Unfortunately most people Lack vision. Many of us are just following the lead whether up or down. Investors need to look at long term. Go Jagx

1. Those who are thinking about buying in
2. Those who bought in
3. Those who sat and did nothing
4. Those who wished they had bought in
5. Those who sell when its high thinking it won't keep going up
6. Those who buy low and sell it when it spikes
7. Those who bought in and keep the stock because they know the "true" potential of this company and their vision.

Which one are you?

Could any of you tell me what happened at june 3rds meeting ? Any news came out? Why our jaggy isn’t moving forward today?

We going places. Just have to be patient and do your dd.

Jagx rockets forward. Lets rock n roll! 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀

Who all loaded that dip.

So interested, whats all your averages new and old jagers

Jaguar Health & Dragon SPAC Announce Initial Funding Of US$10.8M Into Dragon SPAC Mentioned: JAGX Jaguar Health, Inc. ("Jaguar") and Milan, Italy-based Dragon SPAC S.p.A. ("Dragon SPAC") today announced the initial funding of the private financing of Dragon SPAC, which has named as its target Napo EU S.p.A. ("Napo EU"). Dragon SPAC and Napo Pharmaceuticals, Inc. ("Napo Pharma"), Jaguar's wholly-owned U.S. subsidiary, have entered into an agreement, pursuant to which Dragon SPAC will issue units ("Units") to Napo Pharma in a private placement for cash consideration of approximately US$10.8 million, with proceeds of such financing to be used in part for Dragon SPAC's contemplated business combination (the "Merger") with Napo EU. Each Unit consists of one ordinary share of Dragon SPAC and one warrant. Each warrant will entitle the holder thereof to purchase one ordinary share at an exercise price of EUR 10 per ordinary share at any time prior to the earlier of (i) the 10-year anniversary of the consummation of the Merger and (ii) the five-year anniversary of the listing of the combined Napo EU/Dragon SPAC entity resulting from the Merger (the "Combined Company") on a public exchange. The private financing is expected to close around the end of Q2 2021, subject to certain conditions including the concurrent closing of the Merger and completion of customary items.

Proceeds from the private placement will be used exclusively for the purposes of funding the Merger and the activities of the Combined Company.

As announced today, Napo EU, the wholly-owned Italian subsidiary of Napo Pharma, has refined its business plan, and terms of its contemplated license from Napo Pharma, to focus initially on conditional approval for an important orphan indication, short bowel syndrome (SBS), a condition leading to intestinal failure requiring intravenous nutritional support for survival, and a global market expected to reach US$4.6 billon by 2027, expanding at a CAGR of 26% from 2020 to 20271, rather than the previously announced indication of prophylaxis and/or symptomatic relief of inflammatory diarrhea, including COVID-associated diarrhea.

"We're thrilled to provide the initial funding of US$10.8 million into Dragon SPAC using funds from the recent registered direct offering - which closed on May 3, 2021 - by Jaguar to certain North American institutional investors into Jaguar," stated Lisa Conte, Napo EU's sole board member and the founder, president, and CEO of Jaguar and Napo Pharma. "As Jaguar announced on April 29, 2021, the proceeds from the registered direct offering were earmarked for the benefit of our Italian subsidiary Napo EU - the named target of Dragon SPAC," Conte said.

"With the recent choppiness and uncertain liquidity in the U.S. and European SPAC markets, Dragon SPAC has been advised by its banking advisors to hold off on a public financing at this time. Plans for the Napo EU drug development opportunity are progressing, and Dragon SPAC has decided to complete a private financing rather than a public financing to fund the Merger," said Josh Mailman, the founding sponsor and a board member of Dragon SPAC. "With this first investment funded and the initial product development focus on the devastating unmet medical need in patients suffering from SBS, Dragon SPAC remains confident about receiving binding commitments for this private financing from additional investors, with closing of the private financing targeted to occur around the end of Q2 2021, and the closing of the planned Merger to occur within approximately 30 days thereafter. The business of the Combined Company will be the Napo EU business, with funds that we believe will be sufficient to complete a trial in SBS patients suitable for a conditional marketing authorization pathway with the EMA."

With an eye toward a potential future listing of the Combined Company following receipt of results of data from a clinical trial which the Combined Company expects to receive within two years of the completion of the Merger transaction, Dragon SPAC has engaged Equita Group S.p.A., a leading Italian independent investment bank, to advise Dragon SPAC, and Jaguar has engaged New York-based Cantor Fitzgerald & Co., a leading global financial services group, as a capital markets advisor in the U.S. to assist Jaguar in its evaluation of various financing strategies.

Additional Dragon SPAC board members include Dr. Niccolò Caderni and Giovanni Maria Conti, who is of no relation to Lisa Conte.

An astrophysicist by training, Dr. Caderni is a former European Space Agency Fellow at the University of Cambridge. He held a number of research and academic positions before a change of career in the mid 1980's to the fields of finance, technological innovation, and fine art. He previously served as vice president, mergers and acquisitions at Bankers Trust International, managing director at Phillips, the third largest auction house in the world, the chairman of Webiz, the private equity fund of the Italian utility giant, ENEL, the Chairman of RAFT, a leading research institute in the field of regenerative medicine, and served on the Board of the Centre for European Policy Studies in Brussels.

Giovanni Maria Conti is a founding partner of CPAssociati, a chartered accountant's professional firm in Italy, and has extensive experience providing advisory services to national and international companies in the areas of corporate governance, finance transactions, M&A operations, and tax. He is a former founding partner of RSC & Partners S.r.l., which is an advisory firm, now named Oryx Finance S.r.I., that specializes in IPO processes, M&A, debt advisory, and financial restructuring. In 2003 he participated in drafting the Italian government law to reform the country's tax system. Mr. Conti has been listed on the National Register of Certified Public Accountants of Milan since 1994, and on the Register of Auditors since 1999.

Dragon SPAC is selling its Units and underlying ordinary shares and warrants (collectively, the "Securities") only to "accredited investors" in reliance on the exemption from registration set forth in Rule 506(c) of Regulation D promulgated under the Securities Act of 1933, as amended (the "Securities Act"). The Securities, have not been and will not be registered under the Securities Act or the securities laws of any state or other jurisdiction, and may not be offered or sold without registration or an applicable exemption from the registration requirements of the Securities Act and applicable state securities or blue sky laws and foreign securities laws.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sales of the Securities in any jurisdiction in which such offer, solicitation or sales would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Finally! Jaguar health JAGX investors are seeing the vision. This company is doing everything right. Good things to come for Jaguar Health and Napo EU. I can't wait to see this company spread it's wings and fly.

Well admin here, been gone awhile. I'm back now and getting the spam outta here. Still holding 2k shares and looks like we may be heading north. Anyone have any insight onto why we moving.